Trial · NCT07881068
Genetic Basis of SARS-CoV-2 Infection-Associated Multisystem Inflammatory Syndrome in Children (MIS-C)
NCT07881068, Recruiting, Istituto Giannina Gaslini
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Genetic Basis of SARS-CoV-2 Infection-Associated Multisystem Inflammatory Syndrome in Children (MIS-C). Trials, record NCT07881068. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881068
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Genetic Basis of SARS-CoV-2 Infection-Associated Multisystem Inflammatory Syndrome in Children (MIS-C)
- NCT number
- NCT07881068
- Status
- Recruiting
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Istituto Giannina Gaslini
- Conditions
- MIS-C Associated With COVID-19
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical and laboratory characterization of cases enrolled at the IRCCS institutions within the IDEA Network | month 9 | Clinical and laboratory data from patients enrolled at the different IRCCS institutions within the IDEA Network will be collected in a standardized manner using a dedicated clinical data collection form. The collected cases will then be jointly reviewed to assess their eligibility for subsequent analyses. A total of 50 cases will be selected for genomic analyses |
| Primary | Whole-genome sequencing of 50 patient-parent trios. | Month 12 | Identification of candidate genes associated with susceptibility to COVID-19-associated MIS-C and Kawasaki disease. If genomic analysis does not confirm the involvement of single-gene variants in the pathogenesis of MIS-C, an oligogenic and/or multifactorial mechanism should be considered. |
| Primary | Validation of Identified Variants | Month 12 | Following the identification of candidate genes, functional validation will be performed using complementary in silico and in vitro approaches, based on technologies, methodologies, and expertise already available at the participating institutions. In particular, the following studies will be conducted: i) Gene expression studies of candidate genes in patient cells; ii) Generation of mutant cell lines (KO or variant-bearing cell lines) using genome-editing technologies; iii) Transduction of KO cell lines for the gene of interest with viral vectors encoding either the gene carrying the putative pathogenic variant or the wild-type gene; iv) Cellular localization studies of variants considered to be of pathogenic relevance. Patients and their family members will also undergo immunological characterization, with particular focus on mechanisms associated with the inflammatory response and adaptive immunity. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881068
GET https://conductscience.org/api/trials/v1/NCT07881068/registered